UT
USIL Therapeutics develops patented, first-in-class radioprotective medical countermeasures designed for rapid, institutional deployment. These compounds address both acute, high-dose radiation exposure leading to Acute Radiation Syndrome and prolonged, lower-dose exposure encountered in space missions. The company enables governments and allied institutions to protect mission-critical personnel before, during, and after radiological exposure events.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- USIL Therapeutics develops patented, first-in-class radioprotective medical countermeasures designed for rapid, institutional deployment. These compounds address both acute, high-dose radiation exposure leading to Acute Radiation Syndrome and prolonged, lower-dose exposure encountered in space missions. The company enables governments and allied institutions to protect mission-critical personnel before, during, and after radiological exposure events.